Evidence map›Paper›PMID 31897546›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2020

Real-world impact of glucocorticoid replacement therapy on bone mineral density: retrospective experience of a large single-center CAH cohort spanning 24 years.

L L Iervolino, B Ferraz-de-Souza, R M Martin, F C Costa, M C Miranda, B B Mendonça, T S Bachega

Abstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision).Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2022
    Article
  6. Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

L L IervolinoFaculty of Medicine, University of Sao Paulo, Av. Dr. Arnaldo, 455, Sao Paulo, SP, 01246-903, Brazil.ORCID http://orcid.org/0000-0003-4443-5535
B Ferraz-de-SouzaLaboratório de Endocrinologia Celular e Molecular LIM 25 e Unidade de Doencas Osteometabolicas, Divisao de Endocrinologia, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Av. Dr. Arnaldo, 455 sala 4344, Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil.
R M MartinLaboratório de Hormônios e Genética Molecular LIM 42, Divisao de Endocrinologia, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar 155, 2° andar bloco 6, Cerqueira Cesar, Sao Paulo, SP, 05403-900, Brazil.
F C CostaLaboratório de Hormônios e Genética Molecular LIM 42, Divisao de Endocrinologia, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar 155, 2° andar bloco 6, Cerqueira Cesar, Sao Paulo, SP, 05403-900, Brazil.
M C MirandaLaboratório de Hormônios e Genética Molecular LIM 42, Divisao de Endocrinologia, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar 155, 2° andar bloco 6, Cerqueira Cesar, Sao Paulo, SP, 05403-900, Brazil.
B B MendonçaLaboratório de Hormônios e Genética Molecular LIM 42, Divisao de Endocrinologia, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar 155, 2° andar bloco 6, Cerqueira Cesar, Sao Paulo, SP, 05403-900, Brazil.
T S BachegaLaboratório de Hormônios e Genética Molecular LIM 42, Divisao de Endocrinologia, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Av. Dr. Eneas de Carvalho Aguiar 155, 2° andar bloco 6, Cerqueira Cesar, Sao Paulo, SP, 05403-900, Brazil. tbachega@usp.br.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade de São Paulo · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/09674-2
6 · The paper itself

Abstract

The congenital adrenal hyperplasia population seems to have an intrinsic tendency to a high frequency of low bone mass. However in this single-center and long-term evaluated cohort, the simplified corticoid regimen, with exclusive dexamethasone single dose reposition during adulthood, did not represent a risk factor for decrease in bone health.

introductionThe impact of long-term and supposedly physiological doses of gluco and mineralocorticoid (GC/MC) on bone mineral density (BMD) in congenital adrenal hyperplasia (CAH) remains discordant among studies, which contain different clinical forms and corticoid regimens. Our aim was to evaluate the BMD in CAH adults receiving similar GC regimen since childhood and to correlate it with GC/MC cumulative doses.

methodsOnly patients with good compliance, who used cortisone acetate (CA) during childhood and dexamethasone after the final height achievement. Cumulative GC/MC doses were calculated from diagnosis until last evaluation. BMD was analyzed by the first and last energy X-ray absorptiometry (DXA) scans performed.

resultsTwenty simple virilizing (SV) and 14 salt wasting (WS) whose mean age was 26 ± 6 years, mean CA, dexamethasone, and fludrocortisone cumulative doses were 63,813 ± 32,767, 812 ± 558, and 319 ± 325 mg/m

conclusionsEven though a low CA regimen during growth periods in addition to MC replacement appears to have an influence on BMD at femoral sites, interestingly a low dexamethasone one does not seem to be deleterious for bone health in adulthood.

Indexed as

Adrenal Hyperplasia, CongenitalBone DensityAbsorptiometry, PhotonAdultChildGlucocorticoidsHumansRetrospective StudiesYoung AdultGlucocorticoidsBone mineral densityClassical formsCongenital adrenal hyperplasiaCumulative glucocorticoid doseLong-term dexamethasone therapyLow glucocorticoid doses

Identifiers

PMID31897546
OpenAlexW2998225265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.